Calcium_NN Phosphate_NN Nanoparticles_NP Induce_NP Mucosal_NP Immunity_NP and_CC Protection_NP against_IN Herpes_NP Simplex_NP Virus_NP Type_NP 2_CD Previously_RB we_PP reported_VBD that_IN calcium_NN phosphate_NN nanoparticles_NNS (_( CAP_NP )_) represented_VBD a_DT superior_JJ alternative_NN to_TO alum_NN adjuvants_NNS in_IN mice_NNS immunized_VBN with_IN viral_JJ protein_NN ._SENT Additionally_RB ,_, we_PP showed_VBD that_IN CAP_NP was_VBD safe_JJ and_CC elicited_VBD no_DT detectable_JJ immunoglobulin_NN E_NP (_( IgE_NP )_) response_NN ._SENT In_IN this_DT study_NN ,_, we_PP demonstrated_VBD that_IN following_VBG mucosal_JJ delivery_NN of_IN herpes_NN simplex_JJ virus_NN type_NN 2_CD (_( HSV-2_NP )_) antigen_NN with_IN CAP_NP ,_, CAP_NP adjuvant_JJ enhanced_JJ protective_JJ systemic_JJ and_CC mucosal_JJ immunity_NN versus_CC live_JJ virus_NN ._SENT Mice_NNS were_VBD immunized_VBN intravaginally_RB and_CC intranasally_RB with_IN HSV-2_JJ protein_NN plus_CC CAP_NN adjuvant_NN (_( HSV-2+CAP_NP )_) ,_, CAP_NP alone_RB ,_, phosphate-buffered_JJ saline_NN ,_, or_CC HSV-2_NP alone_RB ._SENT HSV-2+CAP_NP induced_VBD HSV-specific_JJ mucosal_JJ IgA_NP and_CC IgG_NP and_CC concurrently_RB enhanced_VBN systemic_JJ IgG_NP responses_NNS ._SENT Our_PP$ results_NNS demonstrate_VBP the_DT potency_NN of_IN CAP_NN as_IN a_DT mucosal_JJ adjuvant_NN ._SENT Furthermore_RB ,_, we_PP show_VBP that_IN systemic_JJ immunity_NN could_MD be_VB induced_VBN via_IN the_DT mucosal_JJ route_NN following_VBG inoculation_NN with_IN CAP-based_JJ vaccine_NN ._SENT Moreover_RB ,_, neutralizing_VBG antibodies_NNS were_VBD found_VBN in_IN the_DT sera_NN of_IN mice_NNS immunized_VBN intranasally_RB or_CC intravaginally_RB with_IN HSV-2+CAP_NP ._SENT Also_RB ,_, the_DT results_NNS of_IN our_PP$ in_IN vivo_JJ experiments_NNS indicated_VBD that_IN mice_NNS vaccinated_VBN with_IN HSV-2+CAP_NP were_VBD protected_VBN against_IN live_JJ HSV-2_NP infection_NN ._SENT In_IN conclusion_NN ,_, these_DT preclinical_JJ data_NNS support_VBP the_DT hypothesis_NN that_IN CAP_NP may_MD be_VB an_DT effective_JJ mucosal_JJ adjuvant_NN that_WDT protects_VBZ against_IN viral_JJ infection_NN ._SENT Since_IN mucosal_JJ surfaces_NNS act_VBP as_IN the_DT primary_JJ point_NN of_IN entry_NN for_IN most_JJS pathogens_NNS and_CC the_DT first_JJ line_NN of_IN defense_NN against_IN them_PP ,_, vaccines_NNS inducing_VBG effective_JJ mucosal_JJ immunity_NN may_MD reduce_VB rates_NNS of_IN infection_NN and_CC decrease_VB the_DT morbidity_NN and_CC mortality_NN of_IN infectious_JJ diseases_NNS ._SENT Currently_RB ,_, no_DT safe_JJ and_CC effective_JJ mucosal_JJ vaccine_NN adjuvants_NNS are_VBP approved_VBN for_IN human_JJ use_NN ._SENT Mucosal_JJ vaccine_NN delivery_NN is_VBZ a_DT promising_JJ strategy_NN ._SENT Mucosal_JJ vaccines_NNS administered_VBN in_IN one_CD part_NN of_IN the_DT body_NN can_MD elicit_VB an_DT antibody_NN response_NN in_IN mucosal_JJ tissues_NNS remote_JJ from_IN the_DT site_NN of_IN initial_JJ antigen_NN exposure_NN ._SENT This_DT effect_NN occurs_VBZ because_IN of_IN the_DT common_JJ mucosal_JJ immune_JJ system_NN ._SENT A_DT major_JJ obstacle_NN to_TO developing_VBG a_DT mucosal_JJ vaccine_NN in_IN humans_NNS is_VBZ finding_VBG a_DT safe_JJ and_CC effective_JJ adjuvant_NN ._SENT Experimental_JJ mucosal_JJ adjuvants_NNS include_VBP cholera_NN toxin_NN ,_, heat-labile_JJ enterotoxin_NN ,_, mutant_JJ toxins_NNS (_( LTK63_NP and_CC LTR72_NP )_) ,_, CpG_NP oligodeoxynucleotide_NN ,_, polymerized_VBN liposomes_NNS ,_, microparticles_NNS ,_, and_CC interleukins_NNS or_CC immune_JJ modulators_NNS ._SENT None_NN of_IN these_DT adjuvants_NNS is_VBZ approved_VBN for_IN use_NN in_IN humans_NNS ._SENT Biodegradable_JJ calcium_NN phosphate_NN particles_NNS have_VBP been_VBN investigated_VBN as_IN an_DT alternative_NN to_TO aluminum_NN adjuvants_NNS for_IN parenteral_JJ vaccines_NNS ._SENT Clinical_JJ studies_NNS conducted_VBN in_IN France_NP described_VBD the_DT use_NN of_IN a_DT calcium_NN phosphate_NN adjuvant_NN for_IN secondary_JJ or_CC booster_NN immunizations_NNS against_IN diphtheria_NN and_CC tetanus_NN ._SENT Calcium_NN phosphate_NN has_VBZ also_RB been_VBN used_VBN for_IN allergen_NN desensitization_NN ._SENT Early_JJ studies_NNS indicated_VBD that_IN calcium_NN phosphate_NN particles_NNS produce_VBP strong_JJ adjuvant_JJ effects_NNS ,_, induced_VBD less_JJR immunoglobulin_NN E_NP (_( IgE_NP )_) than_IN aluminum_NN adjuvants_NNS ,_, and_CC elicited_VBD only_RB minimal_JJ local_JJ irritation_NN in_IN animal_JJ experiments_NNS and_CC human_JJ clinical_JJ trials_NNS ._SENT Here_RB ,_, we_PP describe_VBP a_DT unique_JJ formulation_NN of_IN calcium_NN phosphate_NN nanoparticles_NNS (_( CAP_NP )_) which_WDT is_VBZ distinct_JJ from_IN the_DT formulations_NNS of_IN calcium_NN phosphate_NN described_VBN by_IN European_JJ scientists_NNS and_CC demonstrate_VB its_PP$ use_NN as_IN an_DT effective_JJ mucosal_JJ adjuvant_NN ._SENT Our_PP$ results_NNS indicate_VBP that_IN following_VBG viral_JJ challenge_NN ,_, mice_NNS immunized_VBD with_IN CAP-based_JJ formulations_NNS of_IN herpes_NN simplex_JJ virus_NN type_NN 2_CD (_( HSV-2_NP )_) glycoprotein_NN exhibited_VBD significantly_RB increased_VBN survival_NN rates_NNS and_CC less_JJR severe_JJ clinical_JJ infection_NN than_IN controls_NNS ._SENT These_DT findings_NNS demonstrate_VBP that_IN CAP_NN delivered_VBN as_IN a_DT mucosal_JJ adjuvant_NN confers_VBZ protective_JJ antiviral_JJ immunity_NN ._SENT Formulation_NN of_IN subunit_NN vaccine_NN ._SENT |_SYM The_DT preparation_NN of_IN partially_RB purified_VBN HSV-2_NP glycoproteins_NNS has_VBZ been_VBN described_VBN previously_RB ._SENT Briefly_RB ,_, infected_JJ cells_NNS were_VBD collected_VBN and_CC sonicated_VBN ._SENT The_DT viral_JJ suspension_NN was_VBD centrifuged_VBN at_IN 5,500_CD x_NN g_NN for_IN 15_CD min_NN ._SENT Supernatant_JJ was_VBD collected_VBN and_CC treated_VBN with_IN 1_CD %_NN IGEPAL_NP (_( Sigma_NP Chemical_NP Co._NP ,_, St._NP Louis_NP ,_, Mo._NP )_) lysis_NN buffer_NN for_IN 30_CD min_NN on_IN ice_NN ._SENT The_DT solution_NN was_VBD centrifuged_VBN at_IN 18,500_CD x_NN g_NN for_IN 2_CD h._NN The_DT supernatant_JJ was_VBD dialyzed_VBN against_IN phosphate-buffered_JJ saline_NN (_( PBS_NP )_) at_IN 4C_JJ and_CC stored_VBN at_IN -80C_NN ._SENT Then_RB 1_CD mg_NN of_IN HSV-2_NP protein_NN was_VBD added_VBN to_TO 7.5_CD ml_NN of_IN 12.5_CD mM_NP calcium_NN chloride_NN ,_, followed_VBN by_IN the_DT addition_NN of_IN 7.5_CD ml_NN of_IN 12.5_CD mM_NP dibasic_JJ sodium_NN phosphate_NN and_CC 1.5_CD ml_NN of_IN 15.6_CD mM_NP sodium_NN citrate_NN ._SENT The_DT solution_NN was_VBD stirred_VBN until_IN the_DT final_JJ average_JJ particle_NN size_NN was_VBD less_JJR than_IN 1.2_CD mum_NN ,_, as_RB determined_VBN with_IN a_DT Coulter_NP N4Plus_NP Submicron_NP particle_NN sizer_NN ,_, and_CC was_VBD treated_VBN with_IN 129_CD mM_NP cellobiose_NN overnight_RB ._SENT The_DT total_JJ protein_NN inside_IN CAP_NP was_VBD 123_CD mug_NN ._SENT The_DT particle_NN containing_VBG HSV-2_NP protein_NN was_VBD coated_VBN again_RB with_IN 3.877_CD mg_NN of_IN HSV-2_JJ proteins_NNS by_IN coincubation_NN for_IN 1_CD h_NN at_IN 4C_JJ ._SENT The_DT final_JJ concentration_NN of_IN CAP_NP plus_CC HSV_NP solution_NN was_VBD 2_CD mg_NN of_IN HSV/ml_NP and_CC 10_CD mg_NN of_IN CAP/ml_NP ._SENT The_DT control_NN vaccines_NNS were_VBD PBS_NP ,_, CAP_NP alone_RB ,_, and_CC HSV-2_NP protein_NN alone_RB ._SENT Animals_NNS ._SENT |_SYM Female_NP BALB/c_NP mice_NNS ,_, 6_CD to_TO 8_CD weeks_NNS old_JJ and_CC weighing_VBG 25_CD g_NN ,_, were_VBD obtained_VBN from_IN Charles_NP River_NP Laboratories_NPS ._SENT The_DT mice_NNS were_VBD maintained_VBN in_IN standard_JJ housing_NN with_IN a_DT normal_JJ diet_NN of_IN Purina_NP rodent_NN chow_NN 5001_CD ._SENT Immunization_NN and_CC sample_NN collection_NN ._SENT |_SYM Eight_NP groups_NNS of_IN five_CD female_JJ BALB/c_NP mice_NNS were_VBD inoculated_VBN intravaginally_RB or_CC intranasally_RB with_IN HSV-2+CAP_NP (_( 20_CD mug_NN of_IN viral_JJ protein_NN plus_CC 100_CD mug_NN of_IN CAP_NN per_IN dose_NN per_IN mouse_NN )_) ,_, HSV-2_JJ alone_RB (_( 20_CD mug_NN per_IN dose_NN per_IN mouse_NN )_) ,_, or_CC CAP_NN alone_RB (_( 100_CD mug_NN per_IN dose_NN per_IN mouse_NN )_) in_IN a_DT total_JJ volume_NN of_IN 50_CD mul_NN (_( intravaginally_RB )_) or_CC 10_CD mul_NN (_( intranasally_RB )_) ._SENT The_DT mice_NNS received_VBD two_CD inoculations_NNS ,_, on_IN days_NNS 0_CD and_CC 7_CD ._SENT Samples_NNS were_VBD collected_VBN 7_CD ,_, 14_CD ,_, and_CC 38_CD days_NNS after_IN the_DT last_JJ immunization_NN ._SENT Blood_NN was_VBD obtained_VBN from_IN the_DT orbital_JJ sinus_NN ,_, and_CC the_DT serum_NN samples_NNS were_VBD stored_VBN at_IN -20C_NN ._SENT Mucosal_JJ samples_NNS were_VBD collected_VBN 14_CD days_NNS after_IN the_DT last_JJ immunization_NN by_IN vaginal_JJ lavage_NN with_IN 100_CD mul_NN of_IN PBS_NP ._SENT The_DT sediments_NNS were_VBD removed_VBN by_IN centrifugation_NN ,_, and_CC samples_NNS were_VBD pooled_VBN and_CC stored_VBN at_IN -20C_NN ._SENT ELISA_NP ._SENT |_SYM HSV-specific_NP antibodies_NNS were_VBD detected_VBN by_IN an_DT end-point_NN dilution_NN enzyme-linked_JJ immunosorbent_JJ assay_NN (_( ELISA_NP )_) as_RB described_VBD previously_RB ._SENT Titers_NNS for_IN IgG_NP in_IN plasma_NN samples_NNS were_VBD expressed_VBN as_IN group_NN mean_VBP +-_JJ standard_JJ error_NN of_IN the_DT mean_NN of_IN values_NNS for_IN individual_JJ animals_NNS ._SENT Titers_NNS for_IN IgA_NP and_CC IgG_NP in_IN mucosal_JJ samples_NNS were_VBD expressed_VBN as_IN the_DT mean_NN of_IN triplicate_JJ assays_NNS from_IN pooled_JJ mucosal_JJ samples_NNS ._SENT HSV-2_JJ challenge_NN experiment_NN ._SENT |_SYM Using_VBG methods_NNS reported_VBD previously_RB ,_, mice_NNS were_VBD injected_VBN subcutaneously_RB with_IN DepoProvera_NP (_( Upjohn_NP ,_, Kalamazoo_NP ,_, Mich._NP )_) at_IN a_DT concentration_NN of_IN 2_CD mg/mouse_NN in_IN 50_CD mul_NN of_IN distilled_JJ water_NN on_IN the_DT 45th_JJ day_NN following_VBG primary_JJ immunization_NN ._SENT Five_CD days_NNS later_RBR ,_, the_DT mice_NNS were_VBD challenged_VBN intravaginally_RB with_IN 106_CD PFU_NP of_IN HSV-2_NP ._SENT Mice_NNS were_VBD examined_VBN daily_RB for_IN genital_JJ pathology_NN ,_, and_CC the_DT clinical_JJ scoring_VBG was_VBD performed_VBN by_IN an_DT investigator_NN blinded_VBD to_TO the_DT animal_NN 's_POS immunization_NN status_NN ._SENT Clinical_JJ pathology_NN was_VBD scored_VBN on_IN a_DT 5-point_JJ scale_NN :_: 0_CD ,_, no_DT apparent_JJ infection_NN ;_: 1_LS ,_, slight_JJ redness_NN of_IN external_JJ vagina_NN ;_: 2_LS ,_, severe_JJ redness_NN and_CC swelling_VBG of_IN external_JJ vagina_NN ;_: 3_LS ,_, genital_JJ ulceration_NN with_IN severe_JJ redness_NN ,_, swelling_VBG ,_, and_CC hair_NN loss_NN of_IN genital_JJ and_CC surrounding_JJ tissue_NN ;_: 4_LS ,_, severe_JJ ulceration_NN of_IN genital_JJ and_CC surrounding_JJ tissue_NN and_CC paralysis_NN ;_: and_CC 5_CD ,_, death_NN ._SENT Neutralization_NN assay_NN ._SENT |_SYM As_RB reported_VBN previously_RB ,_, Vero_NP cells_NNS were_VBD propagated_VBN in_IN culture_NN plates_NNS ._SENT Pooled_JJ mouse_NN serum_NN samples_NNS from_IN day_NN 38_CD after_IN the_DT last_JJ immunization_NN were_VBD incubated_VBN with_IN HSV-2_NP and_CC assessed_VBN for_IN the_DT presence_NN of_IN HSV-2-specific_NP neutralizing_VBG antibodies_NNS by_IN plaque_NN assay_NN ._SENT The_DT titer_NN is_VBZ the_DT reciprocal_NN of_IN the_DT serum_NN dilution_NN required_VBN to_TO inhibit_VB the_DT cytolysis_NN of_IN a_DT confluent_JJ monolayer_NN of_IN Vero_NP cells_NNS by_IN 50_CD %_NN ._SENT Statistical_JJ analysis_NN ._SENT |_SYM Pathological_NP data_NNS were_VBD analyzed_VBN by_IN analysis_NN of_IN variance_NN to_TO determine_VB the_DT difference_NN between_IN groups_NNS ._SENT As_IN indicated_VBN in_IN Fig._NN ,_, both_CC the_DT intranasal_JJ and_CC intravaginal_JJ HSV-2+CAP-vaccinated_JJ mice_NNS showed_VBD a_DT high_JJ titer_NN of_IN HSV-specific_NP mucosal_JJ IgA_NP and_CC IgG_NP in_IN vaginal_JJ lavage_NN fluid_NN at_IN 14_CD days_NNS after_IN the_DT last_JJ immunization_NN ._SENT Serological_JJ IgG_NP and_CC IgG2a_NP titers_NNS determined_VBN on_IN day_NN 38_CD after_IN the_DT last_JJ immunization_NN showed_VBD a_DT systemic_JJ response_NN in_IN the_DT mice_NNS after_IN intranasal_JJ or_CC intravaginal_JJ immunization_NN with_IN HSV-2+CAP_NP compared_VBN to_TO PBS_NP ,_, CAP_NP alone_RB ,_, or_CC HSV-2_NP alone_RB ._SENT The_DT neutralization_NN assay_NN was_VBD performed_VBN at_IN day_NN 38_CD following_NN secondary_JJ immunization_NN ._SENT Neutralizing_VBG antibodies_NNS were_VBD found_VBN in_IN both_CC the_DT intranasally_RB and_CC intravaginally_RB HSV-2+CAP-immunized_JJ mice_NNS at_IN titers_NNS of_IN 1:40_CD and_CC 1:80_CD ,_, respectively_RB ._SENT Notably_RB ,_, neutralizing_VBG antibodies_NNS were_VBD absent_JJ in_IN the_DT mice_NNS inoculated_VBN with_IN PBS_NP alone_RB ,_, CAP_NP alone_RB ,_, or_CC HSV-2_NP alone_RB ._SENT Resistance_NN to_TO HSV-2_NP infection_NN was_VBD evaluated_VBN by_IN monitoring_VBG clinical_JJ pathology_NN ._SENT On_IN days_NNS 6_CD ,_, 8_CD ,_, and_CC 10_CD ,_, the_DT reduced_VBN clinical_JJ severity_NN in_IN mice_NNS intravaginally_RB immunized_VBN with_IN HSV-2+CAP_NP achieved_VBD statistical_JJ significance_NN (_( P_NN <_SYM 0.05_LS )_) compared_VBN to_TO mice_NNS immunized_VBN with_IN PBS_NP ,_, CAP_NP alone_RB ,_, or_CC HSV-2_JJ alone_RB (_( Fig._NN ,_, right_JJ panel_NN )_) ._SENT One_CD of_IN five_CD mice_NNS intravaginally_RB inoculated_VBN with_IN HSV-2+CAP_NP died_VBD from_IN HSV-2_NP infection_NN ,_, whereas_IN all_DT of_IN the_DT mice_NNS intravaginally_RB vaccinated_VBN with_IN PBS_NP ,_, HSV-2_NP alone_RB ,_, and_CC CAP_NP alone_RB developed_VBD severe_JJ disease_NN and_CC died_VBD by_IN day_NN 8_CD or_CC 10_CD ._SENT Similarly_RB ,_, the_DT mice_NNS vaccinated_VBD intranasally_RB with_IN HSV-2+CAP_NP showed_VBD reduced_VBN clinical_JJ severity_NN compared_VBN with_IN mice_NNS immunized_VBN with_IN PBS_NP ,_, CAP_NP alone_RB ,_, or_CC HSV-2_NP alone_RB at_IN days_NNS 8_CD and_CC 10_CD (_( Fig._NN ,_, left_VBN panel_NN )_) ._SENT Two_CD of_IN five_CD mice_NNS intranasally_RB vaccinated_VBN with_IN CAP+HSV-2_NP died_VBD ,_, compared_VBN with_IN the_DT controls_NNS (_( i.e._FW ,_, recipients_NNS of_IN PBS_NP ,_, CAP_NP alone_RB ,_, and_CC HSV-2_NP only_RB )_) ,_, all_DT of_IN which_WDT died_VBD eventually_RB ._SENT All_DT surviving_VBG mice_NNS were_VBD kept_VBN for_IN 2_CD more_JJR weeks_NNS and_CC recovered_VBD gradually_RB ._SENT FIG._NN 1_CD ._SENT |_SYM Groups_NNS of_IN five_CD female_JJ BALB/c_NP mice_NNS were_VBD immunized_VBN on_IN days_NNS 0_CD and_CC 7_CD by_IN intranasal_JJ or_CC intravaginal_JJ delivery_NN of_IN PBS_NP (_( vertically_RB striped_JJ bars_NNS )_) ,_, CAP_NN alone_RB (_( open_JJ bars_NNS )_) ,_, HSV-2_JJ alone_RB (_( horizontally_RB striped_JJ bars_NNS )_) ,_, or_CC HSV-2+CAP_NP (_( solid_JJ bars_NNS )_) ._SENT Groups_NNS of_IN five_CD female_JJ BALB/c_NP mice_NNS were_VBD immunized_VBN on_IN days_NNS 0_CD and_CC 7_CD by_IN intranasal_JJ or_CC intravaginal_JJ delivery_NN of_IN PBS_NP (_( vertically_RB striped_JJ bars_NNS )_) ,_, CAP_NN alone_RB (_( open_JJ bars_NNS )_) ,_, HSV-2_JJ alone_RB (_( horizontally_RB striped_JJ bars_NNS )_) ,_, or_CC HSV-2+CAP_NP (_( solid_JJ bars_NNS )_) ._SENT The_DT antigen_NN concentration_NN and_CC vaginal_JJ lavage_NN fluid_NN dilution_NN used_VBN in_IN the_DT ELISA_NP were_VBD 100_CD mug/ml_NN and_CC 1:1_CD ,_, respectively_RB ._SENT FIG._NN 2_CD ._SENT |_SYM The_DT antigen_NN concentration_NN and_CC antibody_NN dilution_NN used_VBN in_IN the_DT IgG_NP ELISA_NP were_VBD 6_CD mug/ml_NN and_CC 1:200_CD ,_, respectively_RB ._SENT The_DT antigen_NN concentration_NN and_CC antibody_NN dilution_NN used_VBN in_IN the_DT IgG_NP ELISA_NP were_VBD 6_CD mug/ml_NN and_CC 1:200_CD ,_, respectively_RB ._SENT The_DT antigen_NN concentration_NN and_CC antibody_NN dilution_NN used_VBN in_IN the_DT IgG2a_NP ELISA_NP were_VBD 100_CD mug/ml_NN and_CC 1:50_CD ,_, respectively_RB ._SENT Each_DT bar_NN represents_VBZ the_DT group_NN mean_JJ antibody_NN level_NN for_IN mice_NNS immunized_VBN intranasally_RB or_CC intravaginally_RB with_IN PBS_NP (_( vertically_RB striped_JJ bars_NNS )_) ,_, CAP_NN alone_RB (_( open_JJ bars_NNS )_) ,_, HSV-2_JJ alone_RB (_( horizontally_RB striped_JJ bars_NNS )_) ,_, or_CC HSV-2+CAP_NP (_( solid_JJ bars_NNS )_) ._SENT FIG._NN 3_CD ._SENT |_SYM Five_NP BALB/c_NP mice_NNS per_IN group_NN were_VBD immunized_VBN intranasally_RB or_CC intravaginally_RB with_IN PBS_NP (_( vertically_RB striped_JJ bars_NNS )_) ,_, CAP_NN alone_RB (_( open_JJ bars_NNS )_) ,_, HSV-2_JJ alone_RB (_( horizontally_RB striped_JJ bars_NNS )_) ,_, or_CC HSV-2+CAP_NP (_( solid_JJ bars_NNS )_) and_CC challenged_VBD intravaginally_RB with_IN 106_CD PFU_NP of_IN HSV-2_NP at_IN 43_CD days_NNS after_IN the_DT last_JJ immunization_NN ._SENT Five_CD BALB/c_NP mice_NNS per_IN group_NN were_VBD immunized_VBN intranasally_RB or_CC intravaginally_RB with_IN PBS_NP (_( vertically_RB striped_JJ bars_NNS )_) ,_, CAP_NN alone_RB (_( open_JJ bars_NNS )_) ,_, HSV-2_JJ alone_RB (_( horizontally_RB striped_JJ bars_NNS )_) ,_, or_CC HSV-2+CAP_NP (_( solid_JJ bars_NNS )_) and_CC challenged_VBD intravaginally_RB with_IN 106_CD PFU_NP of_IN HSV-2_NP at_IN 43_CD days_NNS after_IN the_DT last_JJ immunization_NN ._SENT Clinical_JJ pathology_NN was_VBD scored_VBN as_IN described_VBN in_IN the_DT text_NN ._SENT The_DT stars_NNS indicate_VBP P_NN values_NNS of_IN <0.05_NN for_IN HSV-2+CAP_NP versus_CC PBS_NP ,_, CAP_NP alone_RB ,_, and_CC HSV-2_NP alone_RB ._SENT The_DT mucosal_JJ tissues_NNS are_VBP the_DT primary_JJ routes_NNS of_IN entry_NN into_IN the_DT body_NN for_IN microbial_JJ pathogens_NNS ._SENT Vaccines_NNS inducing_VBG mucosal_JJ immunity_NN prevent_VB the_DT transmission_NN of_IN infection_NN via_IN mucosal_JJ surfaces_NNS ._SENT However_RB ,_, no_DT mucosal_JJ vaccine_NN adjuvant_NN is_VBZ currently_RB approved_VBN for_IN human_JJ use_NN ._SENT Because_IN of_IN the_DT weak_JJ inherent_JJ immunogenicity_NN of_IN some_DT antigens_NNS targeted_VBN for_IN vaccine_NN development_NN ,_, such_JJ as_IN epitope_NN subunits_NN and_CC recombinant_JJ peptides_NNS ,_, there_EX is_VBZ a_DT great_JJ need_NN for_IN safe_JJ and_CC efficient_JJ mucosal_JJ adjuvants_NNS ._SENT The_DT only_JJ adjuvants_NNS used_VBN in_IN licensed_JJ vaccines_NNS in_IN the_DT United_NP States_NPS are_VBP aluminum_NN compounds_NNS ,_, which_WDT effectively_RB enhance_VB immune_JJ responses_NNS ._SENT However_RB ,_, human_JJ studies_NNS have_VBP shown_VBN them_PP to_TO be_VB weak_JJ adjuvants_NNS for_IN inducing_VBG cell_NN and_CC humoral_JJ immunity_NN to_TO some_DT virus_NN protein_NN subunits_NN (_( S._NP J._NP D._NP Bell_NP ,_, personal_JJ observation_NN )_) ._SENT Additionally_RB ,_, alum_NN can_MD elicit_VB an_DT IgE_NP antibody_NN response_NN that_WDT increases_VBZ the_DT risk_NN of_IN allergic_JJ reactions_NNS ._SENT We_PP have_VBP reported_VBN previously_RB that_IN CAP_NP delivered_VBD intraperitoneally_RB with_IN HSV-2_NP and_CC Epstein-Barr_NP virus_NN proteins_NNS induced_VBD high_JJ titers_NNS of_IN IgG2a_NP antibody_NN and_CC neutralizing_VBG antibody_NN and_CC facilitated_VBD a_DT high_JJ degree_NN of_IN protection_NN against_IN viral_JJ infection_NN in_IN a_DT murine_JJ model_NN ._SENT In_IN this_DT study_NN ,_, using_VBG HSV-2_JJ protein_NN as_IN a_DT model_NN antigen_NN ,_, we_PP evaluated_VBD the_DT immunity_NN and_CC efficacy_NN of_IN an_DT HSV-2+CAP_NP experimental_JJ vaccine_NN ._SENT Our_PP$ results_NNS indicated_VBD that_IN mice_NNS vaccinated_VBD either_RB intravaginally_RB or_CC intranasally_RB with_IN HSV-2+CAP_NP had_VBD high_JJ antibody_NN levels_NNS at_IN mucosal_JJ surfaces_NNS and_CC effective_JJ neutralizing_VBG antibody_NN titers_NNS and_CC were_VBD protected_VBN against_IN virus_NN infection_NN ._SENT We_PP assumed_VBD that_IN the_DT neutralizing_VBG antibody_NN prevented_VBD the_DT attachment_NN of_IN pathogens_NNS to_TO the_DT epithelial_JJ surfaces_NNS and_CC conferred_VBD protection_NN against_IN subsequent_JJ viral_JJ infection_NN ._SENT Our_PP$ findings_NNS also_RB confirmed_VBD the_DT previous_JJ studies_NNS showing_VBG that_IN antibodies_NNS can_MD efficiently_RB neutralize_VB virus_NN in_IN mucosal_JJ areas_NNS ._SENT The_DT immune_JJ system_NN within_IN the_DT female_NN lower_RBR genital_JJ tract_NN is_VBZ the_DT initial_JJ defense_NN against_IN sexually_RB transmitted_VBN diseases_NNS ._SENT Our_PP$ study_NN suggested_VBD that_IN intravaginal_JJ immunization_NN induced_VBD relatively_RB higher_JJR levels_NNS of_IN mucosal_JJ IgG_NP and_CC IgA_NP than_IN intranasal_JJ immunization_NN ,_, providing_VBG optimal_JJ protection_NN against_IN HSV-2_NP infection_NN ._SENT This_DT observation_NN supports_VBZ the_DT findings_NNS of_IN others_NNS and_CC suggests_VBZ that_IN genital_JJ local_JJ immunity_NN and_CC Th1_JJ response_NN in_IN association_NN with_IN other_JJ protecting_VBG factors_NNS ,_, such_JJ as_IN local_JJ production_NN of_IN antibodies_NNS and_CC viral_JJ clearance_NN from_IN the_DT vaginal_JJ mucosa_NN ,_, play_VBP a_DT major_JJ role_NN in_IN HSV-2_JJ infection_NN in_IN mice_NNS ._SENT Our_PP$ next_JJ step_NN is_VBZ to_TO prove_VB that_DT CD4+_NP T_NN cells_NNS secreting_VBG gamma_NN interferon_NN and_CC B_NN cells_NNS or_CC natural_JJ antibodies_NNS are_VBP critical_JJ for_IN immune_JJ protection_NN against_IN lethal_JJ genital_JJ HSV-2_NP reinfection_NN ._SENT The_DT exact_JJ mechanism_NN of_IN the_DT adjuvant_JJ action_NN of_IN CAP_NP is_VBZ not_RB fully_RB understood_VBN ._SENT M_NP cells_NNS in_IN the_DT mucosal_JJ tissues_NNS are_VBP known_VBN to_TO reside_VB exclusively_RB in_IN the_DT epithelium_NN and_CC deliver_VB foreign_JJ material_NN by_IN transepithelial_JJ transport_NN from_IN the_DT lumen_NN to_TO the_DT underlying_VBG mucosa-associated_JJ lymphoid_JJ tissue_NN ._SENT Particulate_JJ antigens_NNS are_VBP desirable_JJ because_IN they_PP permit_VBP M_NP cells_NNS to_TO translocate_VB across_IN the_DT tight_JJ epithelial_JJ barrier_NN to_TO mucosal_JJ dendritic_JJ cells_NNS ._SENT Therefore_RB ,_, the_DT particulate_JJ mucosal_JJ vaccine_NN created_VBN from_IN the_DT combination_NN of_IN soluble_JJ antigens_NNS formulated_VBN within_IN CAP_NP provides_VBZ the_DT desirable_JJ size_NN and_CC functional_JJ attributes_NNS to_TO induce_VB effective_JJ mucosal_JJ immunity_NN ._SENT Recent_JJ comparative_JJ studies_NNS have_VBP indicated_VBN that_IN microparticles_NNS are_VBP potent_JJ adjuvants_NNS for_IN mucosal_JJ delivery_NN ._SENT However_RB ,_, microparticles_NNS are_VBP not_RB an_DT ideal_JJ size_NN for_IN inducing_VBG cellular_JJ immunity_NN because_IN they_PP tend_VBP to_TO be_VB too_RB large_JJ ,_, and_CC it_PP is_VBZ believed_VBN that_IN M_NP cells_NNS ,_, dendritic_JJ cells_NNS ,_, macrophages_NNS ,_, and_CC local_JJ lymph_NN nodes_NNS are_VBP more_RBR effective_JJ at_IN taking_VBG up_RP smaller_JJR particles_NNS ._SENT Advantageously_RB ,_, CAP_NP are_VBP generally_RB in_IN the_DT preferred_JJ size_NN range_NN (_( i.e._FW ,_, less_JJR than_IN 1.2_CD mum_NN ,_, versus_CC 1_CD mum-sized_JJ polymers_NNS )_) and_CC also_RB stimulate_VB cellular_JJ immunity_NN and_CC cytotoxic_JJ T_NN lymphocyte_NN responses_NNS (_( unpublished_JJ data_NNS )_) ._SENT Based_VBN on_IN these_DT results_NNS ,_, we_PP conclude_VBP that_IN (_( i_NP )_) the_DT CAP-based_JJ HSV-2_NP subunit_NN vaccine_NN appears_VBZ to_TO concurrently_RB induce_VB both_DT systemic_JJ and_CC mucosal_JJ immunity_NN and_CC (_( ii_NP )_) CAP_NP shows_VBZ great_JJ potential_NN as_IN a_DT safe_JJ and_CC effective_JJ mucosal_JJ vaccine_NN adjuvant_NN for_IN humans_NNS ,_, given_VBN its_PP$ relative_JJ absence_NN of_IN side_NN effects_NNS and_CC lack_NN of_IN IgE_NP antibody_NN induction_NN ._SENT 